Dr. Porter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1211 Fish Hatchery Rd
Madison, WI 53715Phone+1 608-252-8000Fax+1 608-410-2905
Education & Training
Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 2011 - 2014
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2008 - 2011
Medical College of WisconsinClass of 2008
Certifications & Licensure
WI State Medical License 2014 - 2025
IN State Medical License 2012 - 2015
MO State Medical License Active through 2013- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.Linlin Xu, Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan Porter
Haematologica. 2024-07-01 - 34 citationsZanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single...Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan F Porter, John M Burke
The Lancet. Haematology. 2023-01-01 - 34 citationsA Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma.Olumide B. Gbolahan, Ryan F. Porter, John T. Salter, Constantin T. Yiannoutsos, Matthew Burns
Journal of Thoracic Oncology. 2018-12-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
